Michael E. Nassif

6.2k total citations · 3 hit papers
91 papers, 2.2k citations indexed

About

Michael E. Nassif is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Michael E. Nassif has authored 91 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Cardiology and Cardiovascular Medicine, 40 papers in Surgery and 28 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Michael E. Nassif's work include Heart Failure Treatment and Management (39 papers), Diabetes Treatment and Management (28 papers) and Cardiovascular Function and Risk Factors (25 papers). Michael E. Nassif is often cited by papers focused on Heart Failure Treatment and Management (39 papers), Diabetes Treatment and Management (28 papers) and Cardiovascular Function and Risk Factors (25 papers). Michael E. Nassif collaborates with scholars based in United States, Australia and Poland. Michael E. Nassif's co-authors include Mikhail Kosiborod, Shane LaRue, Eric Novak, John A. Spertus, Justin Vader, Suzanne V. Arnold, David S. Raymer, Scott Silvestry, Javed Butler and Philip G. Jones and has published in prestigious journals such as Circulation, Nature Medicine and Journal of the American College of Cardiology.

In The Last Decade

Michael E. Nassif

88 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure

2021 164 citations Michael E. Nassif, Sheryl L. Windsor et al. Circulation profile →
The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

2022 158 citations John A. Spertus, Mary C. Birmingham et al. Nature Medicine profile →
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

2022 119 citations Jan Biegus, Adriaan A. Voors et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael E. Nassif United States	26	1.3k	753	689	527	360	91	2.2k
Lavanya Bellumkonda United States	18	1.0k 0.8×	571 0.8×	293 0.4×	393 0.7×	711 2.0×	62	1.8k
Robert E. Helm United States	24	995 0.8×	1.1k 1.4×	404 0.6×	249 0.5×	431 1.2×	42	2.8k
Veli‐Pekka Harjola Finland	23	2.3k 1.8×	687 0.9×	199 0.3×	725 1.4×	406 1.1×	43	3.2k
John D. Klemperer United States	25	746 0.6×	826 1.1×	692 1.0×	218 0.4×	402 1.1×	35	2.4k
Donata Lucci Italy	29	3.0k 2.2×	616 0.8×	339 0.5×	213 0.4×	229 0.6×	106	3.8k
Justin Vader United States	21	1.1k 0.8×	462 0.6×	174 0.3×	400 0.8×	297 0.8×	76	1.6k
Veli‐Pekka Harjola Finland	26	1.9k 1.5×	749 1.0×	154 0.2×	846 1.6×	526 1.5×	70	3.0k
David D. Berg United States	23	748 0.6×	433 0.6×	227 0.3×	395 0.7×	188 0.5×	82	1.6k
Valentina Carubelli Italy	25	1.5k 1.1×	618 0.8×	144 0.2×	739 1.4×	394 1.1×	58	2.4k
Darlene P. Horton United States	12	2.8k 2.2×	350 0.5×	191 0.3×	513 1.0×	725 2.0×	21	3.2k

Countries citing papers authored by Michael E. Nassif

Since Specialization

Citations

This map shows the geographic impact of Michael E. Nassif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Nassif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Nassif more than expected).

Fields of papers citing papers by Michael E. Nassif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Nassif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Nassif. The network helps show where Michael E. Nassif may publish in the future.

Co-authorship network of co-authors of Michael E. Nassif

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Nassif. A scholar is included among the top collaborators of Michael E. Nassif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Nassif. Michael E. Nassif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tower‐Rader, Albree, et al.. (2025). Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. European Heart Journal.

Hill, C. Larry, Laine Thomas, Michael E. Nassif, et al.. (2024). Association of Medication Adherence and Health Status in Heart Failure With Reduced Ejection Fraction: Insights From the CHAMP-HF Registry. Circulation Cardiovascular Quality and Outcomes. 17(9). e010211–e010211.

Ferreira, João Pedro, Jon Blatchford, John R. Teerlink, et al.. (2023). Mineralocorticoid Receptor Antagonist Use and the Effects of Empagliflozin on Clinical Outcomes in Patients Admitted for Acute Heart Failure: Findings from EMPULSE. European Journal of Heart Failure. 25(10). 1797–1805. 6 indexed citations

Haywood, Hubert B., Gregg C. Fonarow, Muhammad Shahzeb Khan, et al.. (2023). Hospital at Home as a Treatment Strategy for Worsening Heart Failure. Circulation Heart Failure. 16(10). e010456–e010456. 6 indexed citations

Pocock, Stuart, João Pedro Ferreira, Timothy Collier, et al.. (2023). The Win Ratio Method in Heart Failure Trials: Lessons Learnt from EMPULSE. European Journal of Heart Failure. 25(5). 632–641. 19 indexed citations

Arnold, Suzanne V., Daniel N. Silverman, Kensey Gosch, et al.. (2023). Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction. JACC Heart Failure. 11(8). 893–900. 49 indexed citations

Kosiborod, Mikhail, Christiane E. Angermann, Sean P. Collins, et al.. (2022). Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 146(4). 279–288. 93 indexed citations

Selvaraj, Senthil, Zhuxuan Fu, Philip G. Jones, et al.. (2022). Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF. Circulation. 146(11). 808–818. 62 indexed citations

Chaudhry, Sunit‐Preet, Adam D. DeVore, Himabindu Vidula, et al.. (2022). Left Ventricular Assist Devices: A Primer For the General Cardiologist. Journal of the American Heart Association. 11(24). e027251–e027251. 25 indexed citations

10.

Spertus, John A., Mary C. Birmingham, Michael E. Nassif, et al.. (2022). The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nature Medicine. 28(4). 809–813. 158 indexed citations breakdown →

11.

Sperry, Brett W., Mohamed Omer, David M. Safley, et al.. (2021). Influence of Donor Transmitted and Rapidly Progressive Coronary Vascular Disease on Long-Term Outcomes After Heart Transplantation: A Contemporary Intravascular Ultrasound Analysis. Journal of Cardiac Failure. 27(4). 464–472. 14 indexed citations

12.

Sammour, Yasser, Bethany A. Austin, A. Michael Borkon, et al.. (2021). PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. Journal of Cardiac Failure. 27(7). 812–815. 13 indexed citations

13.

Nassif, Michael E., Sheryl L. Windsor, Fengming Tang, et al.. (2021). Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial. Diabetes Obesity and Metabolism. 23(6). 1426–1430. 17 indexed citations

14.

Thomas, Merrill, Yevgeniy Khariton, Gregg C. Fonarow, et al.. (2019). Association of Changes in Heart Failure Treatment With Patients’ Health Status. JACC Heart Failure. 7(7). 615–625. 16 indexed citations

15.

Tahsili‐Fahadan, Pouya, Albert A. Davis, Noushin Yahyavi‐Firouz‐Abadi, et al.. (2018). Cerebrovascular Events After Continuous-Flow Left Ventricular Assist Devices. Neurocritical Care. 29(2). 225–232. 10 indexed citations

16.

Khariton, Yevgeniy, Michael E. Nassif, Laine Thomas, et al.. (2017). Abstract 19403: Gender and Socioeconomic Disparities With Health Status in Outpatients With Heart Failure: Insights From the CHAMP-HF Registry. Circulation. 1 indexed citations

17.

Nassif, Michael E., Yuanyuan Tang, John G.F. Cleland, et al.. (2017). Precision Medicine for Cardiac Resynchronization. Circulation Heart Failure. 10(10). 12 indexed citations

18.

Nassif, Michael E., David S. Raymer, Justin Hartupee, et al.. (2016). A Case Series of Acute Myocardial Infarction in Left Ventricular Assist Device-Supported Patients. ASAIO Journal. 63(2). e18–e24. 6 indexed citations

19.

Sintek, Marc, et al.. (2015). ECHO DERIVED RIGHT VENTRICULAR CONTRACTION PRESSURE INDEX PREDICTS RIGHT VENTRICULAR FAILURE AND MORTALITY IN PATIENTS WITH DURABLE LEFT VENTRICULAR ASSIST DEVICES. Journal of the American College of Cardiology. 65(10). A894–A894. 1 indexed citations

20.

Tahsili‐Fahadan, Pouya, Albert A. Davis, Noushin Yahyavi‐Firouz‐Abadi, et al.. (2015). Ischemic and Hemorrhagic Cerebrovascular Events after Left Ventricular Assist Devices (P2.281). Neurology. 84(14_supplement). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact